CAS Space and Guangzhou Laboratory co-develop a space pharmaceutical payload, aiming for a suborbital test in Q1 2027

According to Xinhuanet, CAS Space and Guangzhou Laboratory have recently begun joint development of a space pharmaceutical payload and plan to validate space drug-manufacturing scenarios together. The first payload is scheduled to fly a suborbital test on the Lihong-2 reusable vehicle in the first quarter of 2027, running protein and small-molecule drug crystallisation experiments as an early technical validation of space pharmaceutical equipment.

In the partnership, Guangzhou Laboratory defines the scientific questions on drug crystallisation and is responsible for the experiment design, samples, ground controls and analysis of results. Its core partner team, led by researcher Xu Qiang, has long worked on high-end medical devices, MEMS (micro-electro-mechanical systems) sensing and microscopic imaging, and is turning mature biomedical automation and in-situ observation capabilities into payload capabilities. CAS Space is responsible for the flight platform, experiment environment, system interfaces, launch and return, and mission organisation; the two jointly carry out the payload's engineering design.

On hardware, the partners will focus on raising the automation of experiment operations and process observation. For a full-field cell imager for space biology experiments, for example, the team has already worked on making it smaller, lighter and lower-power, and on improving autonomous operation and data capture through autofocus, continuous imaging and image analysis. Such technology reduces the use of in-orbit resources and lays a foundation for routine, large-scale use of space biomedical equipment.

Xu Qiang said modern medicine has strong demand for higher-quality structural data, more stable drug crystal forms, disease models closer to the human body and more efficient screening tools, and the space environment may offer new paths for solving some of these problems.

Microgravity is understood to help some proteins form higher-quality crystals and to offer new experimental conditions for crystal-form screening and particle control of small-molecule drugs; cells also form three-dimensional aggregates more readily, which can be used to study disease mechanisms and drug responses.

For space pharmaceuticals to become an industry, however, cost, reproducibility of experimental results and stable product quality still have to be solved. To address this, CAS Space has built the integrity requirements for innovative drug samples into the overall design: each sample gets a unique identifier and a full record of its state; the payload has stronger sealing, contamination protection, temperature holding and shock damping; key environmental parameters are monitored in real time during return; and after landing the samples go through rapid, controlled transfer, so that complete data ensure "space-ground consistency" of the samples.

Our take: this partnership pairs microgravity drug-crystallisation experiments with a reusable vehicle; if validation succeeds it could lower the barrier to entry for space pharmaceuticals, but industrialisation still faces cost and reproducibility challenges.